The radiosensitising effects of Iressa (ZD 1839), an epidermal growth factor receptor tyrosine kinase inhibitor, on related bladder cancer cell lines in vitro

被引：0
|
作者：
Maddineni, SB
Sangar, V
Margison, GP
Hendry, JH
Betts, CD
O'Flynn, KJ
Clarke, NW
机构：
来源：
JOURNAL OF UROLOGY | 2003年 / 169卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
520
引用
收藏
页码：135 / 135
页数：1
相关论文
共 50 条
  • [41] The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-src and pak1 pathways and invasiveness of human cancer cells
    Yang, ZB
    Bagheri-Yarmand, R
    Wang, RA
    Adam, L
    Papadimitrakopoulou, VV
    Clayman, GL
    El-Naggar, A
    Lotan, R
    Barnes, CJ
    Hong, WK
    Kumar, R
    CLINICAL CANCER RESEARCH, 2004, 10 (02) : 658 - 667
  • [42] Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance
    Nakamura, Y
    Oka, M
    Soda, H
    Shiozawa, K
    Yoshikawa, M
    Itoh, A
    Ikegami, Y
    Tsurutani, J
    Nakatomi, K
    Kitazaki, T
    Doi, S
    Yoshida, H
    Kohno, S
    CANCER RESEARCH, 2005, 65 (04) : 1541 - 1546
  • [43] The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines
    Miyata, H
    Sasaki, T
    Kuwahara, K
    Serikawa, M
    Chayama, K
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2006, 28 (04) : 915 - 921
  • [44] Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa)
    Heimberger, AB
    Learn, CA
    Archer, GE
    McLendon, RE
    Chewning, TA
    Tuck, TL
    Pracyk, JB
    Friedman, AH
    Friedman, HS
    Bigner, DD
    Sampson, JH
    CLINICAL CANCER RESEARCH, 2002, 8 (11) : 3496 - 3502
  • [45] Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (′Iressa′) is independent of EGFR expression level
    Campiglio, M
    Locatelli, A
    Olgiati, C
    Normanno, N
    Somenzi, G
    Viganò, L
    Fumagalli, M
    Ménard, S
    Gianni, L
    JOURNAL OF CELLULAR PHYSIOLOGY, 2004, 198 (02) : 259 - 268
  • [46] A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa")
    Yano, S
    Kanematsu, T
    Miki, T
    Aono, Y
    Azuma, M
    Yamamoto, A
    Uehara, H
    Sone, S
    CANCER SCIENCE, 2003, 94 (05) : 453 - 458
  • [47] Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor
    McKillop, D
    Partridge, EA
    Kemp, JV
    Spence, MP
    Kendrew, J
    Barnett, S
    Wood, PG
    Giles, PB
    Patterson, AB
    Bichat, F
    Guilbaud, N
    Stephens, TC
    MOLECULAR CANCER THERAPEUTICS, 2005, 4 (04) : 641 - 649
  • [48] ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy
    Wakeling, AE
    Guy, SP
    Woodburn, JR
    Ashton, SE
    Curry, BJ
    Barker, AJ
    Gibson, KH
    CANCER RESEARCH, 2002, 62 (20) : 5749 - 5754
  • [49] Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer
    Santoro, A
    Cavina, R
    Latteri, F
    Zucali, PA
    Ginanni, V
    Campagnoli, E
    Ferrari, B
    Morenghi, E
    Pedicini, V
    Roncalli, A
    Alloisio, M
    Ravasi, G
    Parral, HJS
    ANNALS OF ONCOLOGY, 2004, 15 (01) : 33 - 37
  • [50] Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2
    J E Nutt
    H P Lazarowicz
    J K Mellon
    J Lunec
    British Journal of Cancer, 2004, 90 : 1679 - 1685
12345